UBS Starts Puma Biotechnology (PBYI) at Buy

On Monday, UBS initiated coverage on Puma Biotechnology (NYSE: PBYI) with a Buy. PT $27.00.

The firm comments, "We believe neratinib, Puma's key asset which it acquired from Pfizer, for HER2+ metastatic breast cancer (mBC) is better than existing chemotherapy alone or Tykerb and see multiple paths to upside from data in the neoadjuvant setting, activity in CNS disease (~30% of all mBC patients) and HER2 lung cancer. We believe mgt. understands how to develop new agents and is shareholder friendly."

For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
• RBC Capital Starts Krystal Biotech (KRYS) at Outperform